In our study, the results of Figure 1 and Figure 2 displayed that after therapy, levels of VEGF, TKI and IL-6 levels, as well as plasma T cells, NK cells together with B cells in the RG presented lower relative to the CG, indicating that rituximab combined with chemotherapy could better reduce the inflammatory response and promote the immune function of DLBCL patients. Here, IL6 is linked to diffuse large B-cell lymphoma.